Filing Details
- Accession Number:
- 0001209191-10-049835
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-10-08 16:10:43
- Reporting Period:
- 2010-10-07
- Filing Date:
- 2010-10-08
- Accepted Time:
- 2010-10-08 16:10:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1006281 | Protalix Biotherapeutics Inc. | PLX | Biological Products, (No Disgnostic Substances) (2836) | 650643773 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1385115 | Yossi Maimon | C/O Protalix Biotherapeutics, Inc. 2 Snunit Street, Science Park, Pob 455 Carmiel L3 20100 | Vp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2010-10-07 | 70,000 | $9.67 | 0 | No | 4 | S | Indirect | By trust |
| Common Stock | Acquisiton | 2010-10-07 | 77,769 | $0.97 | 0 | No | 4 | M | Indirect | By trust |
| Common Stock | Disposition | 2010-10-07 | 7,769 | $9.73 | 0 | No | 4 | F | Indirect | By trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By trust |
| No | 4 | M | Indirect | By trust |
| No | 4 | F | Indirect | By trust |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2010-10-07 | 77,769 | $0.00 | 77,769 | $0.97 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 75,964 | 2016-09-19 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- The reporting person acquired 70,000 shares of common stock upon the exercise of 77,769 outstanding options on a cash-less exercise basis, all of which shares were sold by the reporting person. The Company retained 7,769 shares of common stock in connection with the cashless exercise.
- qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- All options are fully vested.
- Does not include options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019, does not include 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020 and does not include options to purchase 175,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018.
Billionaire Hedge Funds
